BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

37 articles for A Kolesnikov

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
The Rational Design of Selective Benzoxazepin Inhibitors of thea-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).EBI
Genentech
a-Aryl pyrrolidine sulfonamides as TRPA1 antagonists.EBI
Genentech
Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.EBI
Genentech
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): aß-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.EBI
Genentech
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinaseß isoform.EBI
Genentech
Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase.EBI
Genentech
Filling a nick in NIK: Extending the half-life of a NIK inhibitor through structure-based drug design.EBI
Genentech
Potent 4-amino-5-azaindole factor VIIa inhibitors.EBI
Celera Genomics
Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.EBI
Celera Genomics
Factor VIIa inhibitors: improved pharmacokinetic parameters.EBI
Celera Genomics
Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.EBI
Celera Genomics
Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.EBI
Celera
Optimization of a screening lead for factor VIIa/TF.EBI
Axys Pharmaceuticals
Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.EBI
Axys Pharmaceuticals
Development of potent and selective factor Xa inhibitors.EBI
Axys Pharmaceuticals
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.EBI
Genentech
Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.EBI
Genentech
Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity.EBI
Genentech
Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.EBI
Genentech
Discovery of 5-Azaindazole (GNE-955) as a Potent Pan-Pim Inhibitor with Optimized Bioavailability.EBI
Genentech
Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling.EBI
Pharmaron-Beijing
Substituted quinolines useful as kinase inhibitorsBDB
Teligene
Melt-extruded solid dispersions containing an apoptosis-inducing agentBDB
Abbvie
Substituted pyridines as inhibitors of histone deacetylaseBDB
Alkermes
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityBDB
Astex Therapeutics
Treatment and diagnosis of melanomaBDB
Rockefeller University
Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agentsBDB
Gi Therapeutics
4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and painBDB
Pfizer
Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activityBDB
Northwestern University
Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitorBDB
Japan Tobacco
Imidazopyridazine compoundsBDB
Pfizer
Triazolopyrazine derivative and use thereofBDB
Korea Research Institute of Chemical Technology
Synthesis and activity of amides of tripeptides as potential urokinase inhibitors.BDB
Medical University of Bialystok
Inhibitors of cyclophilins and uses thereofBDB
University of Montpellier
A Hexylchloride-Based Catch-and-Release System for Chemical Proteomic Applications.BDB
University of Washington
Carbocyclic influenza neuraminidase inhibitors possessing a C3-cyclic amine side chain: synthesis and inhibitory activity.BDB
Gilead Sciences
Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives.BDB
Yamanouchi Pharmaceutical